OGR for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA)
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
General prescription drug affordability and access. FDA provisions related to prescription drugs; FY2021 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.7610).
| Lobbyist | Covered position, as disclosed |
|---|---|
| DEAN AGUILLEN | — |
| MICHAEL DEE BUCHANAN | — |
| CHRIS GIBLIN | — |
| KARISSA WILLHITE | — |
Medicare/Medicaid MMM
Provisions related to Part D access and drug pricing negotiation. Compulsory licensing policy issues. H.R.1046, Medicare Negotiation and Competitive Licensing Act of 2019. H.R.3, Lower Drug Costs Now Act of 2019. S.2543, Prescription Drug Pricing Reduction Act of 2019. H.R.1425, Patient Protection and Affordable Care Enhancement Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DEAN AGUILLEN | — |
| MICHAEL DEE BUCHANAN | — |
| CHRIS GIBLIN | — |
| KARISSA WILLHITE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.